Importantly, they showed that DCLK1 inhibitor can block cancer stem cells mediated by the CCAR1/β-catenin signaling pathway and thus suppress 5-fluorouracil-resistant CRC cells in vitro and in vivo [7]. This evidence concerns the gene DCLK1 and cancer.